Verified CBD Recaps 2020 CBD Survey Results

American and international respondents provided insight into CBD consumer behavior

MIAMI, FL / ACCESSWIRE / July 28, 2020 / Verified CBD’s recent CBD survey saw 300 respondents provide insight into CBD consumer demographics, preferred products, and motivations for turning to CBD.

The survey found that one of the most common applications for CBD is for pain management and relief, with about 37% of respondents saying that they use CBD products for this purpose. Other common uses include improving mental health (anxiety, stress, and depression) and managing insomnia. The findings of this survey correspond with a Gallup poll conducted in 2019, which found that 40% of American CBD users look to the cannabinoid for pain relief, while 20% use it for anxiety and 11% for insomnia.

Of those surveyed, many say they rely on CBD cream for soothing aches and pains, though capsules and tinctures are also popular CBD products. Gummies are growing in popularity due to their enjoyable flavors and the ability for consumers to take them discreetly almost anywhere.

We’re finding that customers are most concerned with the quality of the CBD they’re purchasing,” says Verified CBD founder Bob Chambers. “Nearly a quarter of our survey respondents said that this was their top concern. Consumers want to feel confident that they’re getting a high-quality product that is potent enough to provide relief from their health symptoms.”

Respondents also indicated concern regarding the efficacy of the CBD products they’re interested in and are interested in learning more about how to find the right dosage.

For more information about the CBD market, product launches, and industry developments, visit verifiedcbd.com or on social @verifiedcbd.

Media Contact:

Maria Harutyunyan
maria.verifiedcbd@gmail.com

SOURCE: Verified CBD

View source version on accesswire.com:
https://www.accesswire.com/598441/Verified-CBD-Recaps-2020-CBD-Survey-Results

Staff

Recent Posts

Rapid Dose Therapeutics Reports Fiscal Year 2024 Financial Results

Burlington, Ontario--(Newsfile Corp. - July 2, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or…

28 mins ago

Zepp Health Introduces Zepp OS 4: Redefining Wearable Intelligence by Integrating OpenAI’s GPT-4o into its Amazfit Smartwatches

Amazfit Active becomes the world's first smartwatch under €200 to fully-integrate AI. MILPITAS, Calif., July…

2 hours ago

Mission Therapeutics awarded $5.2m from The Michael J. Fox Foundation and Parkinson’s UK to advance potential disease-modifying treatment MTX325

Investment will support investigation of Mission's small molecule drug MTX325 in patients with early-stage Parkinson's…

2 hours ago

Clarivate Identifies Six Breakthrough MedTech Trends in 2024 Set to Unlock New Industry Opportunities

New report highlights challenges and opportunities in resilient MedTech industry LONDON, July 2, 2024 /PRNewswire/…

2 hours ago

Poolbeg Pharma PLC Announces Change of Registered Address

Change of Registered AddressLONDON, UK / ACCESSWIRE / July 2, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), ('Poolbeg'…

5 hours ago